Cargando…

Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?

BACKGROUND: Interstitial pneumonia with autoimmune features (IPAF) identifies a recently recognized autoimmune syndrome characterized by interstitial lung disease and autoantibodies positivity, but absence of a specific connective tissue disease diagnosis or alternative etiology. We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Grasselli, Giacomo, Vergnano, Beatrice, Pozzi, Maria Rosa, Sala, Vittoria, D’Andrea, Gabriele, Scaravilli, Vittorio, Mantero, Marco, Pesci, Alberto, Pesenti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603462/
https://www.ncbi.nlm.nih.gov/pubmed/28921478
http://dx.doi.org/10.1186/s13613-017-0320-3
_version_ 1783264701528932352
author Grasselli, Giacomo
Vergnano, Beatrice
Pozzi, Maria Rosa
Sala, Vittoria
D’Andrea, Gabriele
Scaravilli, Vittorio
Mantero, Marco
Pesci, Alberto
Pesenti, Antonio
author_facet Grasselli, Giacomo
Vergnano, Beatrice
Pozzi, Maria Rosa
Sala, Vittoria
D’Andrea, Gabriele
Scaravilli, Vittorio
Mantero, Marco
Pesci, Alberto
Pesenti, Antonio
author_sort Grasselli, Giacomo
collection PubMed
description BACKGROUND: Interstitial pneumonia with autoimmune features (IPAF) identifies a recently recognized autoimmune syndrome characterized by interstitial lung disease and autoantibodies positivity, but absence of a specific connective tissue disease diagnosis or alternative etiology. We retrospectively reviewed the clinical presentation, diagnostic workup and management of seven critically ill patients who met diagnostic criteria for IPAF. We compared baseline characteristics and clinical outcome of IPAF patients with those of the population of ARDS patients admitted in the same period. RESULTS: Seven consecutive patients with IPAF admitted to intensive care unit for acute respiratory distress syndrome (ARDS) were compared with 78 patients with ARDS secondary to a known risk factor and with eight ARDS patients without recognized risk factors. Five IPAF patients (71%) survived and were discharged alive from ICU: Their survival rate was equal to that of patients with a known risk factor (71%), while the subgroup of patients without risk factors had a markedly lower survival (38%). According to the Berlin definition criteria, ARDS was severe in four IPAF patients and moderate in the remaining three. All had multiple organ dysfunction at presentation. The most frequent autoantibody detected was anti-SSA/Ro52. All patients required prolonged mechanical ventilation (median duration 49 days, range 10–88); four received extracorporeal membrane oxygenation and one received low-flow extracorporeal CO(2) removal. All patients received immunosuppressive therapy. CONCLUSIONS: This is the first description of a cohort of critical patients meeting the diagnostic criteria for IPAF presenting with ARDS. This diagnosis should be considered in any critically ill patient with interstitial lung disease of unknown origin. While management is challenging and level of support high, survival appears to be good and comparable to that of patients with ARDS associated with a known clinical insult ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0320-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5603462
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-56034622017-09-27 Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS? Grasselli, Giacomo Vergnano, Beatrice Pozzi, Maria Rosa Sala, Vittoria D’Andrea, Gabriele Scaravilli, Vittorio Mantero, Marco Pesci, Alberto Pesenti, Antonio Ann Intensive Care Research BACKGROUND: Interstitial pneumonia with autoimmune features (IPAF) identifies a recently recognized autoimmune syndrome characterized by interstitial lung disease and autoantibodies positivity, but absence of a specific connective tissue disease diagnosis or alternative etiology. We retrospectively reviewed the clinical presentation, diagnostic workup and management of seven critically ill patients who met diagnostic criteria for IPAF. We compared baseline characteristics and clinical outcome of IPAF patients with those of the population of ARDS patients admitted in the same period. RESULTS: Seven consecutive patients with IPAF admitted to intensive care unit for acute respiratory distress syndrome (ARDS) were compared with 78 patients with ARDS secondary to a known risk factor and with eight ARDS patients without recognized risk factors. Five IPAF patients (71%) survived and were discharged alive from ICU: Their survival rate was equal to that of patients with a known risk factor (71%), while the subgroup of patients without risk factors had a markedly lower survival (38%). According to the Berlin definition criteria, ARDS was severe in four IPAF patients and moderate in the remaining three. All had multiple organ dysfunction at presentation. The most frequent autoantibody detected was anti-SSA/Ro52. All patients required prolonged mechanical ventilation (median duration 49 days, range 10–88); four received extracorporeal membrane oxygenation and one received low-flow extracorporeal CO(2) removal. All patients received immunosuppressive therapy. CONCLUSIONS: This is the first description of a cohort of critical patients meeting the diagnostic criteria for IPAF presenting with ARDS. This diagnosis should be considered in any critically ill patient with interstitial lung disease of unknown origin. While management is challenging and level of support high, survival appears to be good and comparable to that of patients with ARDS associated with a known clinical insult ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0320-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-09-18 /pmc/articles/PMC5603462/ /pubmed/28921478 http://dx.doi.org/10.1186/s13613-017-0320-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Grasselli, Giacomo
Vergnano, Beatrice
Pozzi, Maria Rosa
Sala, Vittoria
D’Andrea, Gabriele
Scaravilli, Vittorio
Mantero, Marco
Pesci, Alberto
Pesenti, Antonio
Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title_full Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title_fullStr Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title_full_unstemmed Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title_short Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
title_sort interstitial pneumonia with autoimmune features: an additional risk factor for ards?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603462/
https://www.ncbi.nlm.nih.gov/pubmed/28921478
http://dx.doi.org/10.1186/s13613-017-0320-3
work_keys_str_mv AT grasselligiacomo interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT vergnanobeatrice interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT pozzimariarosa interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT salavittoria interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT dandreagabriele interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT scaravillivittorio interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT manteromarco interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT pescialberto interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards
AT pesentiantonio interstitialpneumoniawithautoimmunefeaturesanadditionalriskfactorforards